62 results
8-K
EX-4.1
CRVS
Corvus Pharmaceuticals Inc
6 May 24
Entry into a Material Definitive Agreement
4:11pm
Failure, the Company is able to obtain the written consent of a majority of the shares of its issued and outstanding shares of Common Stock to approve
8-K
EX-10.1
CRVS
Corvus Pharmaceuticals Inc
6 May 24
Entry into a Material Definitive Agreement
4:11pm
and Investors holding at least a majority of the Shares and Warrant Shares then held by all Investors (or such Investors’ successors or assigns pursuant
8-K
EX-4.2
f1h59jga
6 May 24
Entry into a Material Definitive Agreement
4:11pm
424B5
bc7dhlf uc0wxzlxj
3 May 24
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
hqy56903mkh
7 Nov 23
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
4:03pm